Real-World Evidence T2D

Post-approval real-world evidence (RWE) is critical for confirming that RCT benefits replicate in clinical practice, particularly in patient populations excluded from trials (older adults, multiple comorbidities, lower socioeconomic status). Multiple real-world T2D studies of tirzepatide have now been published, primarily using US electronic health record databases. The consistent finding: tirzepatide’s HbA1c and weight benefits seen in SURPASS trials translate to real-world T2D practice.

US registry studies (glycaemic and weight outcomes):

Three key observational studies in T2D:

1. HIRD database (PMID 40181696), US commercially insured T2D patients starting tirzepatide May 2022 – January 2023, 6-month follow-up: Significant HbA1c and weight reductions consistent with SURPASS. GLP-1 RA naïve patients showed more pronounced HbA1c reductions; patients with baseline HbA1c <7% showed more weight loss. This confirms the trial observation that response is largest in those with most room for improvement.

2. Urban academic medical centre (PMID 39248221), T2D patients with ≥3 months continuous tirzepatide: Clinically and statistically significant HbA1c and body weight reductions. GLP-1 RA naïve patients showed greater reductions than those switched from GLP-1 RA — consistent with the concept that previous GLP-1 RA use partially “occupies” the GLP-1R pathway.

3. Real-world tirzepatide vs semaglutide T2D (PMC 12579026): Propensity score matched comparison in T2D patients. Tirzepatide favoured over semaglutide for HbA1c and weight reductions — naïve cohort: −3.5% greater weight loss; adjusted analysis: −6.9% weight difference. Consistent with SURPASS-2 direction and magnitude. T2D-specific context noted: weight loss advantage is smaller than in obesity-only populations.

Ontology Real-World Evidence T2D [evidence_for] Tirzepatide Real-World Evidence T2D [relates] SURPASS-2 Real-World Evidence T2D [relates] Semaglutide

TriNetX cardiovascular/mortality signal (important but cautious): A retrospective cohort using the TriNetX global federated database (Science Direct 2024) compared tirzepatide vs semaglutide in T2D patients with obesity (n=8446, propensity score matched 1:1). Tirzepatide was associated with:

• HR 0.54 (95% CI 0.38–0.76; P<0.001) for composite CV outcome
• HR 0.45 (95% CI 0.24–0.84; P=0.010) for cerebral infarction
• HR 0.33 (95% CI 0.15–0.73; P=0.004) for all-cause mortality

These are striking figures — however, observational T2D database studies are prone to healthy user bias (newer, more expensive medications are disproportionately prescribed to healthier patients who are better engaged with healthcare), residual confounding (propensity matching cannot capture all differences), and short follow-up. The SURPASS-CVOT RCT, which rigorously controlled confounders, showed HR 0.92 (non-inferior to dulaglutide; not significantly superior). The TriNetX figures likely overstate the true CV/mortality benefit. They are hypothesis-generating, not confirmatory.

Ontology Real-World Evidence T2D [relates] Cardiovascular Risk Real-World Evidence T2D [relates] SURPASS-CVOT

Who responds most in real-world T2D: Consistent across all real-world studies:

• GLP-1 RA naïve patients (not previously on GLP-1 RA/semaglutide) — largest HbA1c and weight responses
• Higher baseline HbA1c (≥7–8%) — more room for glycaemic improvement
• Patients willing to titrate to higher doses (10–15mg) — greater weight loss
• Younger patients — trend toward greater weight loss (though all age groups benefit)

Evidence Summary

Practical Interpretation

• SURPASS trial results translate: Real-world HbA1c and weight outcomes match the RCT findings
• Superiority over semaglutide holds: Confirmed in multiple real-world T2D datasets
• TriNetX CV/mortality signal: Intriguing but almost certainly overstated — use to support (not replace) SURPASS-CVOT interpretation
• GLP-1 naïve predictors: Clinically useful — patients naïve to GLP-1 RA class will likely show the largest initial response

Connections

• Tirzepatide — evidence_for (real-world confirmation)
• SURPASS-2 — relates (RCT comparison — real-world confirms direction)
• SURPASS-CVOT — relates (CV outcomes RCT vs RWE contrast)
• Semaglutide — compared_against (real-world as well as RCT)
• Cardiovascular Risk — relates (TriNetX CV signal — observational)

Sources

• Real-world T2D tirzepatide vs semaglutide (PMC 12579026)
• US commercially insured T2D (PMID 40181696)
• Urban academic center T2D (PMID 39248221)
• TriNetX real-world CV/mortality (Science Direct 2024)